Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors

SAN FRANCISCO and TAIPEI, Taiwan, Aug. 18, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers …
( read original story …)

---